
The timing is not coincidental. Lockheed and X-Bow both unveiled low-cost counter-UAS solutions within 24 hours at Farnborough, both explicitly framed against the $114-to-1 cost ratio that Pentagon testimony highlighted on July 21.
This convergence signals that industry has identified the same constraint: interceptor depletion is unsustainable, and HPM + kinetic hybrid defense is the near-term solution. If Morfius clears operational testing by Q1 2027, Raytheon faces pressure to justify PAC-3 procurement against a system that costs 1–2% per kill and regenerates. The real competition is not between Lockheed and X-Bow — it's between recoverable/reusable platforms and single-use missiles in the FY27 supplemental.
The Morfius directly targets the cost-per-kill crisis that has drained U.S. interceptor stockpiles during the Iran conflict.
PAC-3 missiles cost $3–5M per shot; X-Bow's Buckler addresses this at sub-$100K per unit; Morfius targets the same asymmetry with a recoverable platform that amortizes cost across 50 kills per sortie. If the system clears field trials in the next 6–9 months, it becomes a cost-effective complement to kinetic interceptors — and a competitive pressure point for Raytheon's Patriot upgrade roadmap. Watch the FY27 budget markup in September for explicit line-item funding; absence signals skepticism about HPM reliability in contested environments.
Does the Morfius HPM architecture actually disable modern Iranian Shahed variants, or is the 50-drone figure based on Group 1–2 threat models? Field test results from Arizona, California, and Oklahoma remain classified — Lockheed's claim needs independent validation against actual threat profiles.
Strategic intelligence, synthesized daily — with a public track record. Every call graded against what actually happened.